Encyclopedia entry · enforcement watch
Melanotan
Melanotan I (afamelanotide, branded Scenesse) and Melanotan II are synthetic analogues of alpha-melanocyte-stimulating hormone (alpha-MSH). Melanotan I has a UK and EU marketing authorisation as Scenesse for erythropoietic protoporphyria, a rare condition. Melanotan II has no marketing authorisation anywhere. Melanotan II is the molecule typically sold as a research peptide for tanning effects, and the MHRA has been actively enforcing against UK consumer-facing sales.
MHRA enforcement context
- · The MHRA has issued multiple public warnings and enforcement actions on Melanotan II since 2008.
- · UK Trading Standards prosecutions on Melanotan have resulted in prison sentences for sellers.
- · Adverse reaction reports include severe nausea, blood pressure changes, and at least one cardiac event reportedly associated with the peptide.
- · Sale for human use is illegal under the Human Medicines Regulations 2012 because it is an unlicensed medicinal product when health claims are made.
- · "Research use only" disclaimers are not a reliable shield for Melanotan II given the active MHRA focus on this molecule specifically.
Why this entry is here
Melanotan II is the highest-enforcement-risk peptide we cover. We include it in the encyclopedia because UK readers searching for it deserve accurate information about the regulatory and safety position. We do not link to retailers from this page. The other research-peptide pages on the site link to retailer comparison; this one deliberately does not.
For erythropoietic protoporphyria specifically, Scenesse (Melanotan I) is the licensed UK route. Speak with a specialist clinician.
Where to learn more
- · MHRA Drug Safety Update bulletins, archived on gov.uk.
- · Trading Standards prosecution case notes (publicly available).
- · Scenesse (afamelanotide) information via the EMA marketing authorisation file.
Popular on PeptideClear
Ready to buy
Buy MELANOTAN in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.